Hjem › B-celle leukemi
Kliniske studier for B-celle leukemi rekrutterer i USA
17 studier for B-celle leukemi rekrutterer deltakere på steder over hele USA.
Byer med flest studier
- Houston, TX7 studier
- Washington, DC5 studier
- Dallas, TX5 studier
- Columbus, OH4 studier
- Portland, OR4 studier
- Philadelphia, PA3 studier
- Spokane, WA3 studier
- Boston, MA3 studier
- New York City, NY3 studier
- San Diego, CA3 studier
- Clifton, NJ3 studier
- Charlotte, NC3 studier
- Louisville, KY3 studier
- Edison, NJ3 studier
- Pittsburgh, PA3 studier
- Chicago, IL3 studier
- Denver, CO3 studier
Etter delstat
- California7 studier
- Colorado3 studier
- Florida3 studier
- Illinois4 studier
- Kansas3 studier
- Kentucky3 studier
- Maryland5 studier
- Massachusetts3 studier
- Minnesota3 studier
- New Jersey4 studier
- New York4 studier
- North Carolina5 studier
- Ohio7 studier
- Oregon4 studier
- Pennsylvania5 studier
- Texas12 studier
- Washington5 studier
Nylig oppdaterte studier
Offisiell studietekst (engelsk)
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT06542250CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
RekruttererFase 1/2
Alder 3 til 39 · Alle kjønn · Oppdatert 30. sep. 2026 · NCT05442515Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
RekruttererObservasjonsstudie
Alder 18 til 110 · Alle kjønn · Oppdatert 28. sep. 2026 · NCT00923507Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
RekruttererFase 4
Alder 18 til 130 · Alle kjønn · Oppdatert 24. sep. 2026 · NCT06651970Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 24. sep. 2026 · NCT04728893Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
RekruttererFase 1
Opp til 75 år · Alle kjønn · Oppdatert 16. sep. 2026 · NCT06345027A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 8. sep. 2026 · NCT06564038Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
RekruttererFase 3
Alder 18 til 18 · Alle kjønn · Oppdatert 8. sep. 2026 · NCT07509151Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)
RekruttererFase 1
12 Months – 25 Years · Alle kjønn · Oppdatert 4. sep. 2026 · NCT05010564Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
RekruttererFase 2
Alder 7 til 25 · Alle kjønn · Oppdatert 19. aug. 2026 · NCT05082519A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 17. aug. 2026 · NCT05254743ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 11. aug. 2026 · NCT07342478A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 31. jul. 2026 · NCT06708897The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
RekruttererFase 1/2
Alder 12 til 95 · Alle kjønn · Oppdatert 15. apr. 2026 · NCT04329728A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
RekruttererFase 2
Alder 18 til 66 · Alle kjønn · Oppdatert 17. mar. 2026 · NCT06859424A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab
RekruttererObservasjonsstudie
Alder 1 til 23 · Alle kjønn · Oppdatert 25. feb. 2026 · NCT07422337Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 22. jan. 2026 · NCT06357754Fra ClinicalTrials.gov, data hentet 4. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.